Compare Diageo plc (DEO) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs Medpace Holdings Inc — how do they compare? Diageo plc trades at $87.13 (market cap $47.67B), while Medpace Holdings Inc trades at $615.8 (market cap $16.82B). The key difference: Diageo plc is far larger — about 2.8× Medpace Holdings Inc's market cap, and Diageo plc pays a 2.3% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and Medpace Holdings Inc for 14 Days on average.
| DEO | MEDP | |
|---|---|---|
Market Cap | $47.67B | $16.82B |
Volume | 893,372 | 223,093 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $630.19 |
52-Week Low | $72.47 | $393.42 |
Typical Hold Time | 66 Days | 14 Days |
Enterprise Value | $68.09B | $16.44B |
Dividend Yield | 2.3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $86.73, up 2.36% with bullish technical indicators and strong analyst support. The company demonstrates solid fundamentals with consistent earnings beats, a 15.82% ROE, and positive cash flow generation. Recent corporate developments include a new CFO appointment and marketing initiatives across key brands, though revenue declined to $19.6B in 2026 with margin compression.
The stock presents a compelling turnaround opportunity with analyst consensus favoring bullish sentiment (48.65% buy ratings). Key catalysts include cost-saving initiatives and brand revitalization, while risks involve US market challenges, regulatory scrutiny in India, and ongoing margin pressure. The current valuation at 27.91 P/E appears reasonable given the growth potential.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
